| Literature DB >> 35812138 |
Wai Mi Aung1, Sarunyoo Songkro2, Supreedee Songkharak2, Nattha Kaewnopparat2, Juraithip Wungsintaweekul1.
Abstract
Croton stellatopilosus (Plaunoi) leaves accumulate several diterpenes and possess various pharmacological activities. The present study aimed to prepare, characterize and assess the antibacterial activity of inclusion complexes prepared by mixing plaunotol (PL) or plaunoi extract (PE) with cyclodextrins (CD), including α-CD, β-CD, γ-CD, and hydroxypropyl-β-cyclodextrin (HP-β-CD). The inclusion complexes were characterized using SEM, XRD, DSC, and FT-IR and evaluated for aqueous solubility and thermal stability. The PL and PE lyophilized complexes with HP-β-CD were further evaluated for their antibacterial activity against acne-causing bacteria. The minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of PL, PE, and the inclusion complexes evaluated using the agar dilution method revealed that the MIC and MBC values of the inclusion complexes were lower than those of PL or PE alone. Interestingly, the complexes had a synergistic activity with clindamycin after testing with checkerboard assay. The hydrogel containing the inclusion complex and clindamycin were assessed for antibacterial activity using the agar well diffusion method. The results indicated that the hydrogels showed significant inhibition of bacterial growth. In conclusion, the prepared solid dispersion of PL or PE with HP-β-CD could enhance antibacterial activity by increasing the drug solubility. The hydrogels containing PL or PE complex and clindamycin could be considered as a candidate for the treatment of acne vulgaris.Entities:
Keywords: Antibacterial activity; CD, cyclodextrin; DSC, Differential scanning calorimetry; FICI, fractional inhibitory concentration index; FT-IR, Fourier-transformed infrared spectrometry; HP-β-CD, hydroxypropyl-β-cyclodextrin; Hydrogel; Hydroxypropyl-β-cyclodextrin; Inclusion complex; KM, kneading method; LM, lyophilized method; MBC, minimal bactericidal concentration; MIC, minimal inhibitory concentration; PE, plaunoi extract; PE:HP-β-CD, inclusion complex of plaunoi extract and hydroxypropyl-β-cyclodextrin; PL, plaunotol; PL:HP-β-CD, inclusion complex of plaunotol and hydroxypropyl-β-cyclodextrin; PM, physical mixture; Plaunoi extract; Plaunotol; SEM, scanning electron microscope; XRD, X-ray diffraction
Year: 2022 PMID: 35812138 PMCID: PMC9257859 DOI: 10.1016/j.jsps.2022.04.004
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.562
Fig. 1Chemical structures: A) plaunotol (PL), B) hydroxypropyl-β-cyclodextrin (HP-β-CD) and C) clindamycin phosphate.
Composition of the hydrogel formulations.
| Active and Excipient | PL:HP-β-CD | PL:HP-β-CD plus clindamycin | PE:HP-β-CD | PE:HP-β-CD plus clindamycin | Clindamycin | Blank |
|---|---|---|---|---|---|---|
| Carbopol® Ultrez 20 | 1.00 g | 1.00 g | 1.00 g | 1.00 g | 1.00 g | 1.00 g |
| 10% w/v NaOH | 4.16 g | 4.16 g | 4.16 g | 4.16 g | 4.16 g | 4.16 g |
| PL:HP-β-CD | 1.00 g | 1.00 g | – | – | – | – |
| PE: HP-β-CD | – | – | 4.54 g | 4.54 g | – | – |
| Clindamycin | – | 0.10 g | – | 0.10 g | 0.10 g | – |
| Distilled water q.s. to | 100 g | 100 g | 100 g | 100 g | 100 g | 100 g |
PL:HP-β-CD 1:2 LM (1 g) contains equivalent of 50 mg of plaunotol.
PE:HP-β-CD 1:2 LM (4.54 g) contains equivalent of 50 mg of plaunotol.
Drug release models and their release kinetic equations.
| Release model | Release kinetic equation |
|---|---|
| Zero order | Q |
| Higuchi | Q |
| First order | Ln Q |
Q = drug release through the membrane (μg/cm2).
t = time.
k0 = rate constant for zero order model.
kh = rate constant for Higuchi model.
kf = rate constant for first order model.
Fig. 2Phase-solubility diagram of plaunotol in aqueous solution of cyclodextrins.
Fig. 3FT-IR spectra of the complexes: A) PL: HP-β-CD 1:1, B) PL:HP-β-CD 1:2, C) PE:HP-β-CD 1:1 and D) PE:HP-β-CD 1:2.
Fig. 4Diffractograms of the complexes: A) PL:HP-β-CD complexes and B) PE::HP-β-CD complexes.
Fig. 5Thermograms of the complexes: A) PL:HP-β-CD complexes and B) PE::HP-β-CD complexes.
Fig. 6Aqueous solubility study: Percent plaunotol dissolved in water A) in PL:HP-β-CD complexes and B) in PE: PE:HP-β-CD complexes. Each point represents mean ± SD, n = 3 where n is the number of samples.
Fig. 7Thermal stability of plaunotol in the complexes: A) PL:HP-β-CD complexes and B) PE::HP-β-CD complexes. Each point represents mean ± SD, n = 3 where n is the number of samples.
Minimum inhibitory concentration (MIC) values and minimum bactericidal concentration (MBC) values for PL, PE and their complexes with HP-β-CD against acne-associated bacteria S. aureus, S. epidermidis and P. acnes.
| Sample | MIC (μg/mL) | MBC (μg/mL) | ||||
|---|---|---|---|---|---|---|
| PL | 500 | 1000 | 500 | 500 | 2000 | 500 |
| PL:HP-β-CD | 500 | 250 | 250 | 500 | 500 | 500 |
| PE | 80 | 80 | 80 | 160 | 160 | 80 |
| PE:HP-β-CD | 25 | 25 | 25 | 100 | 100 | 25 |
| Clindamycin | 31 | 15 | 31 | 31 | 31 | 31 |
| HP-β-CD | >40000 | >40000 | >20000 | >40000 | >40000 | >40000 |
Minimum inhibitory concentration (MIC) values of PL:HP-β-CD, PE:HP-β-CD in combination with clindamycin and fractional inhibitory concentration index (FICI) of the combination the complex with clindamycin.
| Bacteria | MIC (µg/mL) in combination | FICI | MIC (µg/mL) in combination | FICI | ||
|---|---|---|---|---|---|---|
| PL: HP-β-CD | clindamycin | PE: HP-β-CD | clindamycin | |||
| 7.8 | 0.5 | 0.15 | 6.2 | 7.8 | 1.5 | |
| 7.8 | 1.9 | 0.03 | 12.5 | 15.6 | 0.5 | |
| 7.8 | 3.9 | 0.15 | 6.2 | 7.8 | 0.5 | |
FICI value was calculated from the MIC values of single drug from Table 2 and of in combination.
Physical appearance and pH of the hydrogels.
| Hydrogel | Physical appearance | pH (mean ± SD, n = 3) | ||
|---|---|---|---|---|
| freshly prepared | after 6 months | freshly prepared | after 6 months | |
| PL:HP-β-CD | Clear and transparent | Clear and transparent | 6.67 ± 0.01 | 6.67 ± 0.02 |
| PL:HP-β-CD with clindamycin | Clear and transparent | Clear and transparent | 7.33 ± 0.01 | 6.67 ± 0.01 |
| PE:HP-β-CD | Yellowish and translucent | Brownish and translucent | 6.37 ± 0.01 | 6.27 ± 0.02 |
| PE: HP-β-CD with clindamycin | Yellowish and translucent | Brownish and translucent | 6.43 ± 0.04 | 6.24 ± 0.07 |
| Clindamycin | Clear and transparent | Clear and transparent | 6.73 ± 0.01 | 6.80 ± 0.02 |
| Blank | Clear and transparent | Clear and transparent | 6.53 ± 0.02 | 6.87 ± 0.02 |
n = 3, where n is number of sample replicates.
Fig. 8Photomicrographs (300 × ) of hydrogels: A) blank, B) clindamycin, C) PL:HP-β-CD, D) PL:HP-β-CD with clindamycin, E) PE:HP-β-CD and F) PE:HP-β-CD with clindamycin.
Ranges of the pore sizes of the various hydrogels.
| Hydrogel | Pore size (μm) |
|---|---|
| Blank gel | 78–101 |
| Clindamycin | 43–100 |
| PL:HP-β-CD | 54–96 |
| PL:HP-β-CD with clindamycin | 54–89 |
| PE:HP-β-CD | 24–68 |
| PE:HP-β-CD with clindamycin | 28–83 |
Fig. 9Rheograms of freshly prepared hydrogels: A) blank, PL:HP-β-CD, PE:HP-β-CD and B) clindamycin, PL:HP-β-CD with clindamycin, PE:HP-β-CD with clindamycin. Each point represents mean ± SD, n = 3 where n is number of samples.
Fig. 10In vitro plaunotol release from hydrogels in the presence of clindamycin compared with PL hydrogel: A) PL:HP-β-CD complexes and B) PE::HP-β-CD complexes. Each point represents mean ± SD, n = 4 where n is the number of replicates.
Release parameters of plaunotol from different hydrogels.
| Gel formulation | Zero order | Higuchi model | First order | |||
|---|---|---|---|---|---|---|
| r2 | k0 (μg/cm2/h) | r2 | kh (μg/cm2/h1/2) | r2 | kf (1/h) | |
| PL:HP-β-CD | 0.9679 | 6.4691 ± 0.2411 | 0.9991 | 0.7484 | 0.0962 ± 0.0029 | |
| PL:HP-β-CD with clindamycin | 0.8805 | 5.7919 ± 0.4455 | 0.9614 | 0.7051 | 0.0616 ± 0.0036 | |
| PE: HP-β-CD | 0.9858 | 5.3233 ± 0.4314 | 0.9938 | 0.802 | 0.1232 ± 0.0118 | |
| PE: HP-β-CD with clindamycin | 0.9648 | 4.2449 ± 0.3492 | 0.9728 | 0.8944 | 0.0491 ± 0.0034 | |
Each point represents mean ± SD, n = 4 where n is the number of replications.
The release rates of PL:HP-β-CD, PL:HP-β-CD with clindamycin and PE:HP-β-CD hydrogels displayed no significant difference among these three formulations (p > 0.05).
PE:HP-β-CD with clindamycin exhibited the lowest release rate among all hydrogels (p less than 0.05).
Antibacterial activity of hydrogels using agar well diffusion methods.
| Hydrogel | Inhibition zone (mm), (mean ± SD, n* = 3) | ||
|---|---|---|---|
| PL:HP-β-CD | 9.33 ± 0.25 | 9.20 ± 0.34 | 8.73 ± 0.25 |
| PL:HP-β-CD with clindamycin | 28.26 ± 0.23 | 28.13 ± 0.57 | 28.07 ± 0.25 |
| PE:HP-β-CD | 8.00 ± 0.00 | 8.00 ± 0.00 | 8.00 ± 0.00 |
| PE:HP-β-CD with clindamycin | 26.80 ± 0.17 | 22.07 ± 0.87 | 21.36 ± 0.21 |
| Clindamycin | 22.83 ± 0.31 | 20.36 ± 0.40 | 17.53 ± 0.68 |
| Blank | 8.00 ± 0.00 | 8.00 ± 0.00 | 8.00 ± 0.00 |
n* is the number of replicates.
Fig. 11Stability study of hydrogels: A) PL:HP-β-CD, B) PL:HP-β-CD with clindamycin, C) PE:HP-β-CD and D) PE:HP-β-CD with clindamycin. Each point represents mean ± SD, n = 3 where n is the number of samples.